$STTK News

Last published 6d ago

6d agoSTTKShattuck Labs, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
6d agoSTTKShattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in
4w agoSTTKShattuck Labs Announces Two Poster Presentations at UEG Week 2026GlobeNewswireAUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential
2mo agoSTTKShattuck Labs Announces Participation in Upcoming September Investor ConferencesGlobeNewswireAUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential
3mo agoSTTKShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged
5mo agoSTTKShattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingGlobeNewswireAUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially
5mo agoSTTKShattuck Labs, Inc. Announces Proposed Public OfferingGlobeNewswireAUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially
5mo agoSTTKShattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial UpdateGlobeNewswireAUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal
5mo agoSTTKShattuck Labs Announces Phase 1 Results for SL-325GlobeNewswirePotentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higherWell
5mo agoSTTKShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8GlobeNewswireAUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal
6mo agoSTTKShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswirePhase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 –
8mo agoSTTKShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business HighlightsGlobeNewswirePhase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN,
8mo agoSTTKShattuck Labs Announces Participation in Upcoming March Investor ConferencesGlobeNewswireAUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and
9mo agoSTTKShattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology SymposiumGlobeNewswireAUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor
11mo agoSTTKShattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireAUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics
11mo agoSTTKShattuck Labs to Participate in Upcoming December Investor ConferencesGlobeNewswireAUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics
1y agoSTTKShattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker,
1y agoSTTKShattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company PanelGlobeNewswireAUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoIRON STTKShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsGlobeNewswire— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma
1y agoSTTKShattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseGlobeNewswire– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to
1y agoSTTKShattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial
1y agoSTTKShattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 MillionGlobeNewswire– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents
1y agoSTTKShattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and MetabolismGlobeNewswireAUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and
1y agoSTTKShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireAUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody
1y agoSTTKShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025GlobeNewswire– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study –
1y agoSTTKShattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025GlobeNewswireAUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor
1y agoSTTKShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis CongressGlobeNewswireAUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireAUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025GlobeNewswireAUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Announces Participation in Upcoming December ConferencesGlobeNewswireAUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF)
1y agoSTTKShattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected
2y agoSTTKShattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling PathwayGlobeNewswire– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median
2y agoSTTKShattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant
2y agoSTTKShattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology ConferenceGlobeNewswireAUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new
2y agoSTTKShattuck Labs Announces Addition to Russell 2000® and Russell 3000® IndexesGlobeNewswireAUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new
2y agoSTTKShattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) PatientsGlobeNewswire– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not
2y agoSTTKShattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewswireAUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new
2y agoSTTKShattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) PatientsGlobeNewswire- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a
2y agoSTTKShattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 CongressGlobeNewswire– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell
2y agoSTTKShattuck Labs Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society
2y agoSTTKShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewswire– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1
2y agoSTTKShattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireAUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new
2y agoIMNM STTKShattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of DirectorsGlobeNewswireAUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new
2y agoSTTKShattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant
2y agoSTTKShattuck Labs Announces Participation in Upcoming March ConferencesGlobeNewswireAUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new
2y agoSTTKOno Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsPR NewswireOno Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery...
2y agoSTTKShattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory DiseasesGlobeNewswireAUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new
2y agoSTTKShattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024GlobeNewswireAUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new